
Adagio Medical Holdings, Inc.
82
Recent developments highlight regulatory approvals, clinical milestones, leadership changes, and analyst coverage.
- Adagio Medical treated its first patient with the next-generation VCLAS Ultra system in August 2026, marking a clinical milestone [N1].
- The company received FDA IDE approval to study the next-generation VCLAS ventricular ablation system in April 2026 [N4].
- Piper Sandler initiated coverage of Adagio Medical with an overweight recommendation in April 2026 [N2].
- Lake Street initiated coverage with a buy recommendation in December 2025 [N6].
- Deborah Kaster was appointed Chief Financial Officer in addition to her role as Chief Business Officer in September 2025 [N7].
- Insider buying activity was reported in December 2025, indicating insider confidence [N5].
- The company posted a narrower loss in Q2 2025, reflecting some financial improvement [N8].
Adagio Medical Holdings, Inc. operates in the medical device sector, specializing in ventricular ablation systems. The company has developed the next-generation VCLAS Ultra system, which has received FDA investigational device exemption (IDE) approval to conduct clinical studies. The company has initiated patient treatments with this system, marking key clinical milestones. Financially, the company reported positive net income and basic earnings per share for the quarter ending September 30, 2026, though diluted EPS was negative. Liquidity ratios indicate a current ratio below 1.0, suggesting current liabilities exceed current assets. Leadership changes include the appointment of Deborah Kaster as CFO in addition to her existing role. The company has attracted analyst coverage with positive recommendations.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Adagio Medical Holdings, Inc. is a medical device company focused on ventricular ablation technology. The company has recently advanced its next-generation VCLAS Ultra system through FDA IDE approval and patient treatment milestones. Financial disclosures as of September 30, 2026, show a net income of $17.8 million and basic EPS of $2.40, with liquidity ratios indicating current liabilities slightly exceeding current assets. Leadership changes and analyst coverage reflect ongoing corporate developments.
The company has achieved FDA IDE approval for its next-generation VCLAS Ultra system and has begun treating patients, demonstrating progress in clinical development and regulatory pathways. Positive analyst coverage and insider buying activity indicate confidence in the company's prospects. Financial results show net income and basic EPS gains, suggesting operational improvements. Leadership stability with key appointments supports execution capabilities.
Liquidity ratios below 1.0 indicate potential short-term financial constraints, with current liabilities exceeding current assets as of September 30, 2026. Diluted EPS remains negative, reflecting potential dilution or non-operational expenses. The company operates in a competitive medical device market with regulatory and clinical development risks. Execution risks include successful commercialization and scaling of the VCLAS Ultra system beyond initial patient treatments.
Adagio Medical's moat is centered on its proprietary ventricular ablation technology, including the next-generation VCLAS Ultra system, which has secured FDA IDE approval for clinical studies. This regulatory milestone and the initiation of patient treatments provide barriers to entry for competitors. The company's specialized focus on ventricular ablation devices and ongoing clinical development efforts contribute to its competitive positioning in the medical device market.
• Regulatory Risk: The company depends on FDA approvals and regulatory clearances to advance its ventricular ablation systems, which can be delayed or denied.
• Financial Liquidity Risk: Current liabilities exceed current assets, with a current ratio of 0.9 and cash ratio of 0.4 as of September 30, 2026, indicating potential liquidity constraints.
• Clinical Development Risk: The success of the next-generation VCLAS Ultra system depends on clinical trial outcomes and patient treatment results.
• Market Competition Risk: The medical device market for ventricular ablation is competitive, with risks from established players and new entrants.
Business trends: Advancement of next-generation ventricular ablation technology with FDA IDE approval and initial patient treatments.
Execution milestones: Completion of clinical studies, commercialization efforts, and leadership stability.
Key risks: Regulatory approval delays, liquidity constraints, clinical trial outcomes, and competitive market pressures.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Adagio Medical Holdings, Inc. is a U.S.-based company listed on Nasdaq under ticker ADGM [S1].
- As of September 30, 2026, the company reported cash and cash equivalents of $3.1 million and current assets of $6.9 million, with current liabilities of $7.7 million, resulting in a current ratio of 0.9 and a cash ratio of 0.4 [S2].
- The company reported net income of $17.8 million and basic earnings per share of $2.40 for the quarter ending September 30, 2026, while diluted EPS was negative at -5.13 [S2].
- Adagio Medical develops medical devices, including the next-generation VCLAS Ultra ventricular ablation system [N1].
- The company received FDA IDE approval to study the next-generation VCLAS ventricular ablation system as of April 2026 [N4].
- Adagio Medical treated its first patient with the next-generation VCLAS Ultra system in August 2026 [N1].
- Leadership changes include the appointment of Deborah Kaster as Chief Financial Officer in addition to her role as Chief Business Officer as of September 2025 [N7].
- The company has been covered by analysts with positive recommendations, including Piper Sandler initiating coverage with an overweight rating in April 2026 and Lake Street initiating coverage with a buy recommendation in December 2025 [N2][N6].
- Insider buying activity was reported in December 2025 [N5].
- The company posted a narrower loss in Q2 2025, indicating some improvement in financial performance at that time [N8].
Generated 2026-11-16
- S1 | 2026-07-13 | 10-K/A
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-08-04 | www.nasdaq.com | Adagio Medical Treats First Patient With Next-Generation VCLAS Ultra System; Stock Up | https://www.nasdaq.com/articles/adagio-medical-treats-first-patient-next-generation-vclas-ultra-system-stock
- N2 | 2026-04-14 | www.nasdaq.com | Piper Sandler Initiates Coverage of Adagio Medical Holdings (ADGM) with Overweight Recommendation | https://www.nasdaq.com/articles/piper-sandler-initiates-coverage-adagio-medical-holdings-adgm-overweight-recommendation
- N3 | 2026-04-10 | www.nasdaq.com | Weekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO | https://www.nasdaq.com/articles/weekly-buzz-mgnx-resumes-linnet-gsk-wins-china-nod-fda-okays-waters-nbix-snaps-slno
- N4 | 2026-04-08 | www.nasdaq.com | Adaigo Medical Receives FDA IDE Approval To Study Next-Generation VCLAS Ventricular Ablation System | https://www.nasdaq.com/articles/adaigo-medical-receives-fda-ide-approval-study-next-generation-vclas-ventricular-ablation
- N5 | 2025-12-17 | www.nasdaq.com | Wednesday 12/17 Insider Buying Report: SRRK, ADGM | https://www.nasdaq.com/articles/wednesday-12-17-insider-buying-report-srrk-adgm
- N6 | 2025-12-03 | www.nasdaq.com | Lake Street Initiates Coverage of Adagio Medical Holdings (ADGM) with Buy Recommendation | https://www.nasdaq.com/articles/lake-street-initiates-coverage-adagio-medical-holdings-adgm-buy-recommendation
- N7 | 2025-09-08 | www.nasdaq.com | Adagio Medical Chief Business Officer Deborah Kaster Appointed To Addl. Role Of CFO | https://www.nasdaq.com/articles/adagio-medical-chief-business-officer-deborah-kaster-appointed-addl-role-cfo
- N8 | 2025-08-14 | www.nasdaq.com | Adagio Medical Posts Narrower Q2 Loss | https://www.nasdaq.com/articles/adagio-medical-posts-narrower-q2-loss
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


